PMID- 37463703
OWN - NLM
STAT- MEDLINE
DCOM- 20230721
LR  - 20231216
IS  - 1658-3175 (Electronic)
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 44
IP  - 7
DP  - 2023 Jul
TI  - Metabolic and renal outcomes of empagliflozin in patients with type 2 diabetes 
      mellitus attending Armed Forces Hospital in Saudi Arabia: Retrospective cohort 
      study.
PG  - 674-678
LID - 10.15537/smj.2023.44.7.20230094 [doi]
AB  - OBJECTIVES: To explore the effects of empagliflozin (25 mg) on metabolic and 
      renal parameters in patients with type 2 diabetes mellitus (T2DM). METHODS: This 
      retrospective observational comparative study was conducted at a military 
      hospital in southern Saudi Arabia. All adults (aged >18 years) with T2DM who 
      attended diabetic clinics between October 2021 to March 2022 (6 months), with or 
      without insulin treatment, were eligible for inclusion in the study. RESULTS: 
      Following the initiation of empagliflozin treatment, statistically significant 
      reductions in patient weight (kg) were observed at 1, 3-5, and 6 months. In 
      addition, low-density lipoprotein levels significantly decreased 3-5 months 
      post-treatment initiation (p=0.011). However, serum creatinine level decreased 
      gradually with time during the treatment with empagliflozin, from 87.45+/-31.78 
      (0.105) to 78.39+/-27.43 (0.033). Furthermore, after empagliflozin treatment, the 
      urinary albumin-to-creatinine ratio significantly decreased at 3-5 and 6 months. 
      Moreover, HbA1c levels exhibited statistically significant decreases at 3-5 
      months (p<0.001) and at 6 months (p<0.001) following the initiation of 
      empagliflozin treatment. Notably, systolic and diastolic blood pressure 
      significantly reduced 6 months after empagliflozin treatment. CONCLUSION: In the 
      current study, empagliflozin has demonstrated efficacy in controlling blood 
      pressure and body weight, and improving renal function, short-term dyslipidemia, 
      and glycemic control in patients with T2DM.
CI  - Copyright: (c) Saudi Medical Journal.
FAU - Alshahrani, Ali A
AU  - Alshahrani AA
AUID- ORCID: 0000-0001-5333-5814
AD  - From the Department of Family Medicine, Armed Forces Hospital, Khamis Mushait, 
      Kingdom of Saudi Arabia.
FAU - Qahtani, Saad S Al
AU  - Qahtani SSA
AD  - From the Department of Family Medicine, Armed Forces Hospital, Khamis Mushait, 
      Kingdom of Saudi Arabia.
FAU - Qahtani, Abrar S Al
AU  - Qahtani ASA
AD  - From the Department of Family Medicine, Armed Forces Hospital, Khamis Mushait, 
      Kingdom of Saudi Arabia.
FAU - Mashhour, Saeed M
AU  - Mashhour SM
AD  - From the Department of Family Medicine, Armed Forces Hospital, Khamis Mushait, 
      Kingdom of Saudi Arabia.
FAU - Alkhtani, Zayed S
AU  - Alkhtani ZS
AD  - From the Department of Family Medicine, Armed Forces Hospital, Khamis Mushait, 
      Kingdom of Saudi Arabia.
FAU - Alragea, Yahya M
AU  - Alragea YM
AD  - From the Department of Family Medicine, Armed Forces Hospital, Khamis Mushait, 
      Kingdom of Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - HDC1R2M35U (empagliflozin)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - Retrospective Studies
MH  - Saudi Arabia
MH  - Glycated Hemoglobin
MH  - Benzhydryl Compounds/therapeutic use
MH  - Kidney/physiology
MH  - Hospitals
MH  - Hypoglycemic Agents/therapeutic use
PMC - PMC10370372
OTO - NOTNLM
OT  - dyslipidemia
OT  - empagliflozin
OT  - glycemic control
OT  - renal outcomes
OT  - weight
EDAT- 2023/07/19 01:06
MHDA- 2023/07/21 06:44
PMCR- 2023/07/01
CRDT- 2023/07/18 20:43
PHST- 2023/05/22 00:00 [received]
PHST- 2023/06/07 00:00 [accepted]
PHST- 2023/07/21 06:44 [medline]
PHST- 2023/07/19 01:06 [pubmed]
PHST- 2023/07/18 20:43 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - 44/7/674 [pii]
AID - SaudiMedJ-44-7-674 [pii]
AID - 10.15537/smj.2023.44.7.20230094 [doi]
PST - ppublish
SO  - Saudi Med J. 2023 Jul;44(7):674-678. doi: 10.15537/smj.2023.44.7.20230094.